Company: RGNT
Filing Date: 2025-03-11
Form Type: F-1
Source: 0001213900-25-022350
Chunk: 258

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-03-11
Form: F-1
Chunk 258
---
                             
 distribution agent in Israel for Tisseel, for manufacture of GelrinC. The Supply Agreement was amended and restated. The Supply Agreement 
 provides for up to 1,000 kits of Tisseel of the 2 ml Tisseel kit, or 500 kits of Tisseel of the 4 ml Tisseel kit, or 200 kits of          
 Tisseel the 10 ml Tisseel kits per year at a fixed purchase price of $0.136 per unit. The payments under the Supply Agreement are         
 due 30 days from the date of invoice and the Company is subject to a service charge of 1% per month on all amounts past due.              |

The Supply Agreement had an initial term
of 3 years which ended on April 1, 2011; however, the Supply Agreement has an ever-green clause and is automatically renewable for consecutive
1 year terms unless either party gives notice of termination at least 3 months prior to the then current term. The Supply Agreement may
be terminated without cause by Baxter upon 90 days’ prior written notice to the other parties. In addition, either party may terminate
the Supply Agreement in the event of an uncured material breach or insolvency.

| 4. | In March 2019, the Company participated                                                                                             
 in the Horizon 2020 Research and Innovation Framework Programme from European Union through the European Commission Executive       
 Agency for Small and Medium-sized Enterprises (the “EASME”) for its participation in research and development activities            
 of the Company. Pursuant to the participation in the Programme, the EASME will fund R&D expenses up to total approved budget        
 of approximately $2,680 (EURO 2,185 thousand), out of which $1,095 (EURO 983 thousand) was received in 2019 and $1,039 (EURO        
 874 thousand) was received in 2021. As of December 31, 2023, the Company, recorded the amount received as a grant liability in      
 other accounts payable in balance sheets.                                                                                           
 In April 2024, the Company submitted the                                                                                            
 final report to the Programme and received a notification that the Programme was completed and also received the remaining grant    
 funds at the amount of approximately $350 (EURO 327 thousands). Following the completion of the Programme, the Company recorded all 
 of the grant amount received as a reduction in research and development expenses.                                                   |

| 5. | In January 202